Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12186367
Isoform Nell-1 peptide
granted -
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted -
US 12187746
C26-linked rapamycin analogs as mTOR inhibitors
granted -
US 12187762
Dithiolsaccharide mucolytic agents and uses thereof
granted -
US 12186314
Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
granted -
IT 202300014295
COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO
granted -
US 12194059
Compositions comprising citrate and applications thereof
granted -
US 12195766
Tumor-selective E1a and E1b mutants
granted -
US 12195454
Compounds for imaging tau proteins that accumulate in the brain
granted -
US 12194065
Methods and compositions to enhance metabolic detoxification systems
granted -
US 12194150
Levodopa dosing regimen
granted -
US 12194091
Antibodies that bind human C6 and uses thereof
granted -
US 12195535
Antibodies binding to VISTA at acidic pH
granted -
US 12194078
Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
granted -
US 12194082
Compositions and methods for treatment of homocystinuria
granted -
US 12194049
Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection
granted -
US 12194081
ARGINASE1 polypeptides
granted -
US 12195439
C1-substituted isopropylamine fused heterocyclic mescaline derivatives
granted -
US 12194090
Tetanus vaccine platform for embedding COVID-19 vaccine
granted -
US 12195804
Treatment of squamous cell carcinoma
granted -
US 12194079
Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
granted -
US 12194061
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 12195773
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12195724
Methods of producing T cell populations enriched for stable regulatory T-cells
granted -
US 12194138
Devices and methods for delivering therapeutics
granted -
US 12195453
Antiproliferation compounds and uses thereof
granted -
US 12195768
System and method for modulating stress granule assembly
granted -
US 12194064
Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids
granted -
US 12195447
Azolopyrimidine for the treatment of cancer-related disorders
granted -
US 12194016
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12194084
Multi-subunit vaccines to elicit both MHC- and CD1-restricted T cell responses
granted -
US 12195558
Targeted delivery system and methods of use therefor
granted -
US 12195620
Controlled entrapment and release of molecular cargo
granted -
US 12195540
Antibodies that bind integrin αvβ8 and uses thereof
granted -
CN 119325492
Fluorescent probe targeting CA-IX
granted -
US 12201721
Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
granted -
US 12202798
Antimicrobial compounds, compositions, and articles of manufacture for selectively inhibiting pathogenic microbes
granted -
US 12202797
Method for producing pyrrole compound
granted -
US 12201598
Immunoregulatory microparticles for modulating inflammatory arthritides
granted -
US 12201604
Treatment of circadian rhythm disorders
granted -
US 12201685
Methods of modulating immune responses with cationic lipid vaccine compositions
granted -
US 12201655
Antimicrobial therapy
granted -
US 12201593
Oral pharmaceutical formulations of bitter compounds for asthma
granted -
US 12201601
Treatment for obesity
granted -
US 12201699
Compositions and methods for promoting homology directed repair
granted -
US 12201683
Methods for preventing dengue and hepatitis a
granted -
CN 119343336
1, 4-bis-(2-hydroxy-benzyl)-1, 4, 7-triazacyclononane derivatives and similar compounds as ligands in iron (iii) complexes for use as MRI contrast agents
granted -
US 12202880
HLA engineering methods and compositions for treatment of autoimmunity
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.